Skip to main content

. 1995 May;58(5):638–639. doi: 10.1136/jnnp.58.5.638

Interferon-alpha may benefit steroid unresponsive chronic inflammatory demyelinating polyneuropathy.

M Sabatelli, T Mignogna, G Lippi, M Milone, V Di Lazzaro, P Tonali, E Bertini

PMCID: PMC1073503 PMID: 7745420

638

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Durelli L., Bongioanni M. R., Cavallo R., Ferrero B., Ferri R., Ferrio M. F., Bradac G. B., Riva A., Vai S., Geuna M. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology. 1994 Mar;44(3 Pt 1):406–413. doi: 10.1212/wnl.44.3_part_1.406. [DOI] [PubMed] [Google Scholar]
Papo T., Piette J. C., Du L. T., Godeau P. Interféron alpha et auto-immunité. Ann Med Interne (Paris) 1993;144(5):357–366. [PubMed] [Google Scholar]
van Doorn P. A. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 1994 Nov;57 (Suppl):38–42. doi: 10.1136/jnnp.57.suppl.38. [DOI] [PMC free article] [PubMed] [Google Scholar]

ACTIONS

RESOURCES